Quarterly Updates30 Jul 2025, 01:56 pm
Suven Life Sciences Ltd Reports Negligible Revenue and Increased Losses in FY25
AI Summary
Suven Life Sciences Ltd, a company focused on developing solutions for Central Nervous System (CNS) related ailments, has reported a significant decrease in revenue and a substantial increase in losses in the Financial Year 2024-25. The company's revenue has halved from ~13 crore in FY21 to less than 7 crore in FY25. The negative EBITDA has doubled from -80 crore in FY21 to -2166 crore in FY25. The net loss has catapulted from 272 crore in FY21 to 161 crore in FY25. Despite these challenges, the company remains optimistic and continues to invest in its robust pipeline of 13 novel molecules for various CNS ailments.
Key Highlights
- Revenue in FY25 is less than half of FY21's revenue
- Negative EBITDA has doubled from FY21 to FY25
- Net loss has increased significantly from FY21 to FY25
- Suven Life Sciences Ltd remains focused on developing solutions for CNS-related ailments
- The company has a robust pipeline of 13 novel molecules for various CNS ailments